NeuroDerm Announces Second Quarter 2016 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update

REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ: NDRM ), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.

“We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from Parkinson’s disease,” said Oded Lieberman, PhD, CEO of NeuroDerm.  “We announced that Trial 005, evaluating ND0612H to DUODOPA® in a head-to-head pilot pharmacokinetic study, achieved comparable results in patients with severe Parkinson’s disease.  In addition, we have commenced enrolling patients in three important clinical trials: our first clinical trial for ND0701 (trial 101), our continuous, subcutaneously delivered liquid apomorphine-base formulation; a Phase II trial of ND0612H (trial 006) for severe Parkinson’s disease; and a Phase III trial of ND0612L (trial 007, named the “iNDiGO” trial) in patients with moderate Parkinson’s disease.  We look forward to meeting with the FDA in late October to discuss our clinical development program and plan to hold a similar meeting with the EMA later this year,” concluded Dr. Lieberman.

Recent Highlights

  • Initiation of a Phase III efficacy trial for ND0612L (trial 007; “iNDiGO”).
  • Presentation of the study design of the Phase II clinical trial of ND0612H (trial 006) as well as preclinical data on the Company’s new apomorphine product candidate ND0701 at the 20th International Congress of Parkinson’s Disease and Movement Disorders.
  • Announced ND0612H achieved comparable pharmacokinetics to DUODOPA® in head-to-head pilot PK comparison trial (trial 005).
  • Started U.S. patient enrollment in a Phase II trial (trial 006) to investigate the efficacy, safety, tolerability and pharmacokinetics of ND0612H to the baseline oral standard of care.
  • Announced key management additions: Tami Yardeni as Chief Operating Officer and Eran Shor as Vice President of Devices.
  • Announced the first clinical study (trial 101) for ND0701, a continuous subcutaneously delivered liquid apomorphine-base product candidate for the treatment of advanced Parkinson’s disease, in a bioequivalence trial in healthy volunteers.
  • Recent tests have demonstrated that, after thawing, ND0612 is stable for up to thirty-five days at room temperature.

Upcoming 2016 Milestones

The currently anticipated timelines for the Company’s ongoing and upcoming clinical trials are as follows:

ND0612H

  • Efficacy, safety, tolerability and pharmacokinetics study (US) (trial 006): ongoing; trial completion expected in the second half of 2016.
  • Definitive PK Study (EU) (trial 009): initiation expected at the end of 2016 or beginning of 2017.
  • Phase III efficacy trial (US) (trial 010): initiation expected at the end of 2016 or beginning of 2017.    

ND0701

  • Bioequivalence trial (EU) (trial 101): ongoing, trial completion expected in the fourth quarter of 2016.

Financial Results for the Quarter Ended June 30, 2016

Research and development expenses, net were $5.6 million in the three months ended June 30, 2016 compared to $3.3 million in the same period in 2015.  The increase was primarily due to an increase in subcontractors and materials, mainly from clinical studies and due to costs related to the development of our devices.

General and administrative expenses were $1.4 million in the three months ended June 30, 2016 compared to $1.0 million in the same period in 2015. The increase was primarily due to an increase in share-based compensation expenses.

The Company reported a net loss of $7.0 million in the three months ended June 30, 2016 compared to $5.8 million for the same period in 2015.  The increase in net loss was primarily due to the increase in research and development expenses, net, which were partially offset by a decrease in financial expenses as a result of a change in our functional currency, from New Israel Shekel to the U.S. dollar, effective January 1, 2016.

As of June 30, 2016, the Company had cash and cash equivalents and short-term bank deposits totaling $89.8 million.

NeuroDerm is a clinical-stage pharmaceutical company with a limited operating history, has not yet generated revenue from its operations and continues to incur significant research and development and other expenses related to its ongoing operations.  The Company is still in the early stages of development of its product candidates.  Accordingly, there is no assurance that NeuroDerm’s business will generate positive cash flow.  As of June 30, 2016, NeuroDerm had an accumulated deficit of $160.5 million and its activities have been funded through public and private offerings of the company’s securities and issuance of convertible loans and warrants.

Conference Call Details

NeuroDerm will host a conference call at 8:30 a.m. ET today to discuss the Company’s second quarter 2016 financial results.  Individuals can access the webcast in the Events and Presentations section of the Company’s website, by clicking here , or by dialing 844-452-2810 (U.S.) or 574-990-9831 (outside of the U.S.).  The passcode is 51507650.  A webcast will be archived on the website.

About NeuroDerm NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration.  The company has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease.  The company has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD.  The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously.  In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD.  NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.

Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Financial Tables Follow

NEURODERM LTD.
STATEMENTS OF FINANCIAL POSITION
(Unaudited)
(U.S. dollars in thousands, except share data)
 
        December 31,   June 30,
Assets:       2015   2016
                 
Current Assets:          
Cash and cash equivalents       $ 84,735     $ 73,692  
Short- term bank deposits         15,103       16,074  
Prepaid expenses and receivables         625       1,525  
          100,463       91,291  
Non-Current Assets :          
Restricted bank deposit         104       105  
Long-term prepaid expenses         149       152  
Property, plant and equipment, net         152       676  
          405       933  
Total  Assets       $ 100,868     $ 92,224  
                     
NEURODERM LTD.
STATEMENTS OF FINANCIAL POSITION
(Unaudited)
(U.S. dollars in thousands, except share data)
 
  December 31,   June 30,
Liabilities and Shareholders’ Equity: 2015   2016
               
Liabilities:    
     
Current Liabilities:    
Accounts payable:    
Trade $ 592     $ 1,866  
Other   3,176       3,441  
    3,768       5,307  
Shareholders payable   44       44  
Total  Liabilities   3,812       5,351  
Shareholders’ Equity:              
Share capital:    
Ordinary Shares, NIS 0.01 par value –              
authorized – 160,000,000 shares at December 31, 2015 and June 30, 2016, issued and outstanding – 21,609,787 shares and 21,704,426 at December 31, 2015 and June 30, 2016, respectively   37       37  
Additional paid-in capital   239,293       239,486  
Share-based compensation capital reserve   8,004       9,928  
Accumulated deficit   (148,238 )     (160,538 )
Foreign currency translation differences   (2,040 )     (2,040 )
Total Shareholders' Equity   97,056       86,873  
Total  Liabilities And Shareholders' Equity $ 100,868     $ 92,224  
               
NEURODERM LTD.
STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(U.S. dollars in thousands, except per share data)
 
    Six months ended June 30,   Three months ended June 30,
    2015   2016   2015   2016
Operating expenses:                              
Research and development $ 5,509     $ 9,686     $ 3,689     $ 5,556  
Participation in research and development   (483 )     -       (368 )     -  
Research and development, net   5,026       9,686       3,321       5,556  
General and administrative   1,890       3,000       950       1,448  
Operating loss   6,916       12,686       4,271       7,004  
Financial income   384       391       44       56  
Financial expenses   867       5       1,597       2  
Financial expenses (income),  net   483       (386 )     1,553       (54 )
Net loss   7,399       12,300       5,824       6,950  
Other comprehensive income -                              
Items that will not be reclassified        
to profit or loss -        
Foreign currency translation differences   (1,086 )     -       (1,990 )     -  
Total comprehensive loss $ 6,313     $ 12,300     $ 3,834     $ 6,950  
Basic and diluted loss per ordinary share $ 0.44     $ 0.57     $ 0.34     $ 0.32  
                               
NEURODERM LTD.
STATEMENTS OF CASH FLOWS
(Unaudited)
(U.S. dollars in thousands)
     
    Six months ended   Three months ended
  June 30,   June 30,
    2015   2016   2015   2016
                                 
     
Cash Flows From Operating Activities:          
Net loss   $ (7,399 )   $ (12,300 )   $ (5,824 )   $ (6,950 )
Adjustments in respect of:          
Depreciation     20       31       10       20  
Share-based compensation to employees and service providers     1,052       1,924       498       1,129  
Interest and exchange differences on bank deposits and                                
restricted bank deposits     1,107       28       1,121       (46 )
Exchange differences in respect of cash and cash equivalents     (297 )     (60 )     442       106  
      (5,517 )     (10,377 )     (3,753 )     (5,741 )
Changes in asset and liability items:                                
Decrease (increase) in prepaid expenses and receivables                                
(including non-current portion)     (314 )     (817 )     251       (337 )
Increase (decrease) in accounts payable:          
Trade     260       948       (101 )     341  
Other     (258 )     93       992       (253 )
Payment of shareholders' interest payable     (993 )     -       (131 )     -  
      (1,305 )     224       1,011       (249 )
Net cash used in operating activities     (6,822 )     (10,153 )     (2,742 )     (5,990 )
Cash flows from investing activities:                                
Purchase of property, plant and equipment     (48 )     (57 )     (45 )     (20 )
Investment in short- term bank deposits     (23,510 )     (24,000 )     -       -  
Proceeds from short-term bank deposits     -       23,000       -       8,000  
Restricted bank deposits, net     -       -       (1 )     -  
Net cash provided by (used in) investing activities     (23,558 )     (1,057 )     (46 )     7,980  
Cash flows from financing activities:                                
Proceeds from exercise of options granted to employees     -       107       -       107  
Net cash provided  from financing activities       -       107       -       107  
Increase (decrease) in cash and cash equivalents     (30,380 )     (11,103 )     (2,788 )     2,097  
Balance of cash and cash equivalents at beginning of period     43,238       84,735       15,425       71,701  
Foreign currency translation differences                                
in respect of cash and cash equivalents     (144 )     -       816       -  
Exchange differences in respect of cash and                                
cash equivalents     297       60       (442 )     (106 )
Balance of cash and cash equivalents at end of period   $ 13,011     $ 73,692     $ 13,011     $ 73,692  
Supplementary information:                                
Interest received from cash and cash equivalents and bank deposits   $ 21     $ 363     $ 5     $ 133  
Investing activities not involving cash flows-                                
Purchasing of property, plant and equipment on credit     -     $ 498       -     $ 498  
                                 

 

NeuroDerm Contact:   Oded S. Lieberman, PhD, CEO  oded@neuroderm.com  Tel.: +972-8-946 2729  Cell: +1-617-517 6077

U.S. Investor Contact:   David Carey  Lazar Partners Ltd.  dcarey@lazarpartners.com  +212-867-1762

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 120

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 100

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading